Trials / Completed
CompletedNCT00180115
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The AML96 study examines the feasibility of a risk-adapted postremission treatment strategy including related and unrelated allogeneic stem cell transplantation for high risk AML patients and related allogeneic and autologous stem cell transplantation for standard risk AML patients in a multi-center setting. Furthermore it randomizes patients between intermediate-dose Cytarabine vs high-dose Cytarabine within the first postremission-course.
Detailed description
The AML96 study examines the feasibility of a risk-adapted postremission treatment strategy including related and unrelated allogeneic stem cell transplantation for high risk AML patients and related allogeneic and autologous stem cell transplantation for standard risk AML patients in a multi-center setting. Furthermore it randomizes patients between intermediate-dose Cytarabine vs high-dose Cytarabine within the first postremission-course.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cytarabine Dosage |
Timeline
- Start date
- 1996-02-01
- Completion
- 2008-11-01
- First posted
- 2005-09-16
- Last updated
- 2007-07-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00180115. Inclusion in this directory is not an endorsement.